Healthcare / Medical DevicesNasdaqGM
$1.95
+0.03 (+1.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 28% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-45.0M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
2/9
balance/quality
Valuation
0/100
-75.4% upside
5Y CAGR
-12.7%
0/100
Data QA
100/100
SEC 100%
Sin guardar todavía.
Market Cap
$136M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-53.7%
↓Gross Margin
-98.2%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-345.6%
FCF / Net income
0.60x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $13.0M · net income $-75.0M · FCF $-45.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC | 2018SEC |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $13.0M | $13.0M | $11.3M | $9.9M | $8.6M | $1.3M | — | — | — |
| Net Income | $-75.0M | $-75.0M | $-53.5M | $-60.8M | $-113.2M | $-61.8M | $-43.8M | $-22.6M | $-1.9M |
| EBITDA | $-49.0M | $-49.0M | $-45.0M | $-47.8M | $-75.7M | — | — | — | — |
| EPS | -1.16 | -1.16 | -0.91 | -1.08 | -2.17 | -1.28 | -1.23 | — | — |
| Gross Margin | -98.2% | -98.2% | -94.0% | -66.6% | -80.2% | -116.0% | — | — | — |
| Operating Margin | -600.8% | -600.8% | -502.9% | -631.9% | -1372.2% | -4720.7% | — | — | — |
| Net Margin | -576.1% | -576.1% | -474.3% | -613.6% | -1320.2% | -4739.1% | — | — | — |
| Balance Sheet | |||||||||
| Debt/Equity | 0.06 | 0.06 | 0.02 | 0.02 | 0.02 | — | — | — | — |
| Current Ratio | 3.96 | 3.96 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-45.0M | $-45.0M | $-39.4M | $-48.1M | $-50.6M | $-61.2M | $-35.5M | $-5.6M | $-3.7M |
| Returns | |||||||||
| ROE | -53.7% | -53.7% | -28.3% | -31.1% | -52.3% | -21.2% | -19.0% | -257.0% | -29.9% |
| Valuation | |||||||||
| P/B | 0.00 | 0.00 | 0.00 | 0.00 | 0.42 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 15.4% | 15.4% | 13.9% | 15.5% | 557.8% | — | — | — | — |
| EPS Growth | -27.5% | -27.5% | 15.7% | 50.2% | -69.5% | -4.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-61.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.91 → -1.16
Residual
-61.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.